Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· February 2, 2026

Mawson Infrastructure Group Inc. Adopts Limited Duration Stockholder Rights Agreement

View original at globenewswire.com
Mawson Infrastructure Group Inc. Adopts Limited Duration Stockholder Rights Agreement MIDLAND, Pa., Feb. 02, 2026 (GLOBE NEWSWIRE) -- MAWSON INFRASTRUCTURE GROUP Inc…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Endeavor purported combined ownership of shares amounting to 48.0% of shares outstanding as of January 28, 2026

    80% confidence

  • The Rights Agreement does not preclude the Board from considering proposals, engaging in discussions or pursuing transactions that it believes are in the best interests of Mawson and its stockholders

    80% confidence

  • Endeavor purported combined ownership of shares amounting to 31.6% of shares outstanding as of January 6, 2026

    80% confidence

  • Based on Mawson's records, Endeavor's purported 48.0% ownership actually amounted to 29.7% of shares outstanding

    80% confidence

  • Based on Mawson's records, Endeavor's purported 31.6% ownership actually amounted to 19.5% of shares outstanding

    80% confidence

  • The Rights Agreement is intended to enable Mawson's stockholders to realize the long-term value of their investment and protect its stockholders from actions of third parties that the Board determines are not in the best interests of Mawson and its stockholders

    80% confidence

  • Endeavor did not have any present plan or proposal that would result in an extraordinary corporate transaction or a change in the Board or management of the Company

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com